Jounce Therapeutics, Inc. (Nasdaq: JNCE) to Ring the Nasdaq Stock Market Closing Bell
ADVISORY, Jan. 26, 2018 (GLOBE NEWSWIRE) --
What:Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Richard Murray, PH.D., CEO & President, will ring the Closing Bell.
Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:Monday, January 29, 2018 – 3:45 p.m. to 4:00 p.m. ET
Jounce Therapeutics Media Contact:Komal Joshi(857) 320-2523[email protected]
Nasdaq MarketSite Media Contact:Emily Pan(646) 441-5120[email protected]
Feed Information:Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Jounce Therapeutics: Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
About Nasdaq:Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-